551 Health claim verifications avg. score 5.1/10 219 rated (mostly) true 266 rated (mostly) false
“Sessions at clinics in Auckland, New Zealand, typically cost NZ$80–NZ$140 each.”
The claim overstates what a typical Auckland clinic visit costs. Many routine GP and general clinic appointments, especially for enrolled patients, are commonly below NZ$80, often in roughly the NZ$26–NZ$65 range. NZ$80–NZ$140 is more characteristic of higher-priced subsets such as urgent care, non-enrolled or visitor consults, and some private or specialized services, not clinic sessions overall.
“Fruit remains in the human stomach for only about 15 minutes after being eaten.”
The 15-minute figure is not supported by clinical evidence. Whole fruit is a structured, fiber-containing food, not a clear liquid, and standard medical sources describe stomach emptying for solids in hours rather than minutes. Even unusually fast estimates for some fruits are generally above 15 minutes and do not justify a broad claim about all fruit.
“Kūmarahou (Pomaderris kumeraho) does not kill bacteria and is not an antibacterial agent.”
The evidence does not support a blanket denial of antibacterial activity. Peer-reviewed lab studies found kūmarahou extracts inhibited at least two human pathogens, S. aureus and B. cereus, which qualifies as antibacterial activity under standard testing. Evidence for broad bactericidal effects or clinical benefit is more limited, but that caveat does not rescue the claim’s absolute wording.
“Triptans are taken during a migraine attack, not before or after it.”
The evidence shows triptans are primarily acute medicines used to stop or reduce an ongoing migraine attack, not preventive drugs taken in advance or treatments used after the attack has ended. The main caveat is that some guidelines allow them during aura, which can occur before headache pain but is still part of the migraine attack.
“Kūmarahou does not have universally agreed dosage guidelines.”
The evidence supports the claim. Authoritative regulatory and scientific sources do not show any globally or broadly standardized dosage guideline for kūmarahou, while available dosing advice varies across traditional, practitioner, and commercial sources. Some guidance exists, but it is local and non-universal rather than a single agreed standard.
“The gut-brain axis is a real biological communication system between the gastrointestinal tract and the brain.”
The core claim is well supported by mainstream biomedical literature. The gut-brain axis refers to real, bidirectional communication between the gastrointestinal tract and the brain via neural, hormonal, immune, and microbial pathways. What remains unsettled are some specific mechanisms and clinical implications, not the existence of gut-brain communication itself.
“The human gut microbiome produces enough neurotransmitters to directly influence human personality traits and temperament.”
The evidence does not support a direct microbiome-to-personality effect through microbial neurotransmitters. Gut microbes do make neuroactive chemicals, but these generally do not cross into the brain in amounts that would directly shape personality or temperament. Current human research mainly suggests indirect gut-brain signaling and possible links to mood or symptoms, not proven direct control of stable personality traits.
“Most digestive enzymes produced by the small-intestinal wall are bound to the apical (brush-border) cell membrane of intestinal epithelial cells rather than being freely secreted into the intestinal lumen.”
The evidence supports the core claim: small-intestinal digestive enzymes are predominantly brush-border membrane proteins, especially disaccharidases and many peptidases. A minor fraction can be shed into the lumen, and not every enzyme in intestinal cells is brush-border bound, but those caveats do not overturn the main point.
“The study described in PubMed Central article PMC12952596 was a randomized clinical trial with a sample of 212 adults.”
The study is well-supported as a randomized clinical trial in adult cancer patients, but the specific claim that it had a sample of 212 adults is not directly confirmed in the evidence provided. Multiple authoritative records identify the article and its trial design. However, none of the cited excerpts actually quote the participant count, and planned enrollment may differ from the final analyzed sample.
“Pigs are currently the generally accepted source species for xenotransplantation into humans due to their physiological similarity to humans and the ability to scale production.”
Current evidence supports pigs as the accepted source species for human xenotransplantation. The main reasons cited across reviews and clinical updates are functional organ and metabolic compatibility with humans, plus practical scalability through breeding and genetic engineering. The key caveat is that this compatibility is engineered and still faces major immune barriers, so acceptance refers to research and early clinical practice, not routine transplantation.
“There is a real, documented organ shortage crisis.”
The evidence strongly supports the existence of a persistent organ shortage. Official transplant data and peer-reviewed studies show that demand for organs continues to exceed supply, producing large waitlists and ongoing deaths among patients awaiting transplants in both the U.S. and globally. Rising transplant numbers and some improved outcomes indicate progress, not resolution of the shortage.
“In New Zealand, having fewer than 9 deceased organ donors per million people results in hundreds of patients dying each year while waiting for organ transplants.”
The claim is not supported by current New Zealand evidence. Recent official and medical sources place deceased donor rates above 9 per million in many recent years, and the available waiting-list mortality figures are far below “hundreds each year.” Patients do die waiting for transplants, but this claim overstates both the donor-rate problem and the scale of deaths.
“In 2011, there were 400 people on the transplant waiting list in New Zealand.”
The claim is directionally accurate but not exact. The strongest official evidence puts New Zealand’s organ transplant waiting list at 420 people on 31 December 2011, while other sources describe the figure more loosely as about 400 to 500. Saying “400” is a reasonable approximation, but it understates the specific official year-end count and leaves out that the list changed over time.
“Living Cell Technologies conducted clinical trials in New Zealand in which islet cells from Auckland Island pigs were transplanted into eight patients with type 1 diabetes.”
The central claim is well supported: Living Cell Technologies did conduct New Zealand clinical studies using Auckland Island pig islet cells in patients with type 1 diabetes. The problem is the number. Eight patients matches an intermediate stage reported at the time, but the completed New Zealand trial later treated 14 patients, so the claim is accurate in substance but incomplete as stated.
“Pancreatic proteases such as trypsinogen and chymotrypsinogen are synthesized as inactive zymogens and are activated in the duodenum by an intestinal enzyme (enterokinase/enteropeptidase), which helps prevent autodigestion of the pancreas.”
The claim matches standard human physiology. Pancreatic proteases are secreted as inactive precursors, and enteropeptidase in the duodenum initiates their activation by converting trypsinogen to trypsin, which then activates other zymogens. Delaying activation until the intestine is an important safeguard against pancreatic autodigestion, though not the only one.
“During emulsification in digestion, each microscopic fat droplet contains only lipids inside, bile salts form an outer coating with their hydrophobic ends facing inward and hydrophilic ends facing outward, and water surrounds the droplet outside this coating.”
The claim captures the basic textbook picture of fat emulsification, but it overstates how neat the molecular structure is. Bile salts do orient with hydrophobic regions toward lipid and hydrophilic regions toward surrounding water, so water is outside the droplet. However, real digestive droplets are not best described as a perfectly pure lipid core wrapped by a simple bile-salt shell.
“Consuming sugary drinks before midnight makes babies hyperactive and less likely to fall asleep at their usual bedtime.”
The evidence does not support this claim. Research and pediatric guidance do not show that sugar itself makes babies acutely hyperactive, and the better-supported sleep concern in sweet drinks is caffeine, not sugar alone. The claim also invents a "before midnight" cutoff and extends findings from older children or long-term observational studies to babies and same-night bedtime effects without evidence.
“Reduced perfusion of the small-intestinal mucosa can impair enterocyte renewal and contribute to villous blunting (villous atrophy), reducing absorptive surface area.”
Evidence supports this mechanism. Reduced small-intestinal mucosal perfusion can impair epithelial renewal, promote enterocyte loss, and contribute to villous blunting, which lowers absorptive surface area. The strongest data come from ischemia, shock, and sustained hypoperfusion models, but the claim is appropriately cautious in saying this can occur and can contribute.
“During an acute stress response, splanchnic vasoconstriction reduces gastrointestinal perfusion and prioritizes blood flow to the heart, lungs, and skeletal muscle.”
The statement captures the main physiology: acute sympathetic activation constricts the splanchnic circulation, lowering gastrointestinal blood flow and helping preserve perfusion for the heart and active skeletal muscle. The weak point is "lungs": pulmonary flow usually rises because cardiac output rises, not because blood is selectively diverted there. Many references also emphasize preservation of brain perfusion and arterial pressure.
“Villous blunting can reduce intestinal absorption of nutrients including glucose, amino acids, and fat-soluble vitamins.”
The evidence supports the claim. Villous blunting decreases absorptive surface and functional capacity in the small intestine, which can reduce absorption of glucose, amino acids, and fats; fat-soluble vitamin deficits commonly follow from impaired fat absorption. Severity varies by how extensive the villous damage is, but the basic statement is accurate.